Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial - Röllig, Christoph; Serve, Hubert; Hüttmann, Andreas; Noppeney, Richard; Müller-Tidow, Carsten; Krug, Utz; Baldus, Claudia D.; Brandts, Christian H.; Kunzmann, Volker; Einsele, Hermann; Krämer, Alwin; Schäfer-Eckart, Kerstin; et al. (The lancet. Oncology, 2015)
Gesehen am 02.07.2020